GSK buys Chimagen's trispecific T-cell engager for up to $750M
Illustration (decorative, not data).Summary
GSK acquired global rights from Chimagen to a trispecific T-cell engager for multiple myeloma: one arm binds T cells and the other two bind two undisclosed tumor-associated antigens. It is still preclinical; GSK expects it to enter Phase 1 in 2027. The dual-antigen design targets the antigen loss and relapse commonly seen after single-target T-cell engagers (such as BCMA) and CAR-T. This is the second time GSK has bought an asset from Chimagen; the earlier CMG1A46 is a different molecule. Together with Roche's September in-licensing of Simcere Zaiming's CD79a×CD19×CD3, trispecifics are becoming a new deal hotspot in antibody engineering.
Deal terms, as disclosed
Upfront undisclosed + development and commercial milestones (up to $750M combined).
Summary of public disclosures, not investment advice. Amounts are as announced; milestone payments are contingent and may never be paid.
Related same deal type
Asset owners and investors: write to bd@inlightbio.com. Newsletter and report questions: contact@inlightbio.com.